Value through Innovation27 July 2016

What is a lay summary?

Clinical Study Results

  • BI 836826 - Lymphoma, Large B-Cell, Diffuse
    Clinical Study Number 1270.11
    Study Indication Lymphoma, Large B-Cell, Diffuse
    Product BI 836826
    Generic Name BI 836826
    Lab Code BI 836826
    Clinical Phase I/II
    Study Title

    An Open Label Multicenter Phase Ib/II Trial to Determine the Dose of BI 836826 in Combination With Gemcitabine and Oxaliplatin (GemOx) and the Efficacy of BI 836826-GemOx Versus Rituximab (R)- GemOx (R-GemOx) in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma (DLBCL) Who Are Not Eligible for, or Have Relapsed/Progressed After Autologous/Allogeneic Stem Cell Transplant

    Study Document
    Trial synopsis 1270.11 english